EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients

Gonzalo Ruiz, Diego Enrico iD, Yamil D Mahmoud, Alan Ruiz, María Florencia Cantarella, Laura Leguina, Mariana Barberis, Asunción Beña, Esteban Brest, Solange Starapoli, Andrea Mendoza Bertelli, Florencia Tsou und 11 weitere

Thoracic Cancer · 2024-04 · 15 (11) · 895-905

DOI: 10.1111/1759-7714.15244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 08.03.2024. Verfasst von Gonzalo Ruiz und 22 weiteren Autor:innen. Beteiligte Einrichtung: Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive biomarker of response to immune checkpoint blockade in non‐small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD‐L1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America.

Methods

This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD‐L1 expression concurrently with genomic alterations in the driver genes EGFR , ALK , ROS1 , BRAF , and/or KRAS G12C in FFPE tissue samples.

Results

A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD‐L1 expression was categorized as PD‐L1 negative (45.1%), PD‐L1 positive low‐expression 1%–49% (32.3%), and PD‐L1 positive high‐expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD‐L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively ( p < 0.001 and p = 0.013). Tumors with non‐adenocarcinoma histology had a significantly higher median PD‐L1 expression ( p < 0.001). Additionally, PD‐L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14–2.25, p < 0.01]). In the multivariate analysis, EGFR ‐positive tumors were more commonly associated with PD‐L1 low expression (OR 0.62 [95% CI: 0.51–0.75], p < 0.01), while ALK‐positive tumors had a significant risk of being PD‐L1 positive (OR 1.81 [95% CI: 1.30–2.52], p < 0.01).

Conclusions

PD‐L1 expression was associated with well‐defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD‐L1 in patients with advanced NSCLC in a large Latin American cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinomaMaleHumansProtein-Tyrosine KinasesB7-H1 AntigenRetrospective StudiesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsMutationErbB Receptors

Stichwörter der Autor:innen

driver mutationsgenomic alterationsimmunohistochemistry (IHC)non‐small cell lung cancer (NSCLC)programmed death‐ligand 1 (PD‐L1)

Substanzen

Protein-Tyrosine KinasesB7-H1 AntigenAnaplastic Lymphoma KinaseProto-Oncogene ProteinsErbB Receptors

Autor:innen und Institutionen

  • Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina.
  • Thoracic Oncology Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
  • Clinical Research Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
  • Universidad Argentina de la Empresa (UADE), Instituto de Tecnología (INTEC), Buenos Aires, Argentina.
  • Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • Medical Oncology Unit, Hospital Zonal Especializado en Agudos y Crónicos Dr. Antonio Cetrangolo, Buenos Aires, Argentina.

ORCID-Profile: Diego Enrico, Claudio Martín

Zitieren

APA

Ruiz, G., Enrico, D., Mahmoud, Y. D., Ruiz, A., Cantarella, M. F., Leguina, L., Barberis, M., Beña, A., Brest, E., Starapoli, S., Mendoza Bertelli, A., Tsou, F., Pupareli, C., Coppola, M. P., Scocimarro, A., Sena, S., Levit, P., Perfetti, A., Aman, E., …, & Salanova, R. (2024). Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients. Thoracic Cancer, 15(11), 895-905. https://doi.org/10.1111/1759-7714.15244

Vancouver

Ruiz G, Enrico D, Mahmoud YD, Ruiz A, Cantarella MF, Leguina L, et al. Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients. Thoracic Cancer. 2024;15(11):895-905. doi:10.1111/1759-7714.15244

BibTeX
@article{Ruiz2024,
  author = {Ruiz, Gonzalo and Enrico, Diego and Mahmoud, Yamil D and Ruiz, Alan and Cantarella, María Florencia and Leguina, Laura and Barberis, Mariana and Beña, Asunción and Brest, Esteban and Starapoli, Solange and Mendoza Bertelli, Andrea and Tsou, Florencia and Pupareli, Carmen and Coppola, María Pía and Scocimarro, Alejandra and Sena, Susana and Levit, Patricio and Perfetti, Aldo and Aman, Enrique and Girotti, María Romina and Arrieta, Oscar and Martín, Claudio and Salanova, Rubén},
  title = {Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {11},
  pages = {895--905},
  doi = {10.1111/1759-7714.15244}
}
Kostenlos starten →